Should all infants be vaccinated against meningococcus?

Meningococcal Vaccination in Infants: Risk-Based, Not Universal

No, routine meningococcal vaccination is not recommended for all infants in the United States—only for those at increased risk for meningococcal disease. The standard U.S. immunization schedule reserves meningococcal vaccination for adolescents (starting at age 11-12 years) and for infants/young children with specific high-risk conditions 1.

Who Should Receive Meningococcal Vaccination in Infancy

High-Risk Infants Requiring Vaccination

Meningococcal vaccination is indicated for infants aged 2-23 months with the following conditions 1:

• Anatomic or functional asplenia (including sickle cell disease)
• Persistent complement component deficiencies (C3, C5-C9, properdin, factor D, factor H)
• Complement inhibitor use (eculizumab, ravulizumab)
• HIV infection 1
• Travel to or residence in hyperendemic/epidemic areas (e.g., meningitis belt of sub-Saharan Africa) 2
• Outbreak situations involving vaccine-preventable serogroups 1

Vaccine Selection by Age and Risk

For infants 2-23 months at increased risk 1:

• MenACWY-CRM (Menveo) is the preferred option for infants starting at 2 months:

  • If initiated at 2 months: 4-dose series at 2,4,6, and 12 months
  • If initiated at 7-23 months: 2 doses (second dose ≥12 weeks after first and after 1st birthday)

• MenACWY-D (Menactra) can be used starting at 9 months:

  • 2 doses given ≥12 weeks apart

• MenB vaccines are NOT recommended for infants under 10 years unless part of an outbreak response 1

Critical Timing Considerations

Interaction with Other Vaccines

For children with asplenia or HIV infection, special precautions apply 1:

• MenACWY-D (Menactra) should not be given before age 2 years in these populations due to interference with pneumococcal conjugate vaccine (PCV) response
• If MenACWY-D must be used, wait at least 4 weeks after completing all PCV doses 1
• MenACWY-CRM or MenACWY-TT are preferred alternatives that don't have this interaction 1

Booster Dosing for High-Risk Children

Children who remain at increased risk require boosters 1:

• If vaccinated before age 7 years: Booster every 3 years
• If vaccinated at age ≥7 years: Booster every 5 years

Why Not Universal Infant Vaccination?

The U.S. does not recommend universal infant meningococcal vaccination despite infants having higher disease incidence for several reasons:

Epidemiologic considerations: While infants do have elevated risk, the overall incidence of invasive meningococcal disease in the U.S. remains low in the general infant population 3, 4. The burden is concentrated in specific high-risk groups and adolescents.

Serogroup distribution: Serogroup B causes most infant disease in the U.S., but MenB vaccines are not licensed for infants under 10 years 1. The available MenACWY vaccines cover serogroups that are more prevalent in adolescents and young adults.

Programmatic focus: The U.S. strategy prioritizes adolescent vaccination (ages 11-12 and 16 years) when disease risk resurges and social mixing increases transmission 1.

International Context

The United Kingdom provides a contrasting approach: England introduced universal infant MenB vaccination (4CMenB/Bexsero) in 2015 with a reduced 2-dose infant schedule plus 12-month booster 5. This program demonstrated:

• 75% reduction in serogroup B disease in vaccine-eligible cohorts
• Vaccine effectiveness of 59.1% with the full 3-dose schedule
• An estimated 277 cases prevented over 3 years 5

This demonstrates that universal infant meningococcal vaccination can be effective when implemented, but the U.S. has chosen a different risk-based strategy given its distinct epidemiology.

Common Pitfalls to Avoid

• Don't delay vaccination in high-risk infants: These children need early protection, starting as young as 2 months with MenACWY-CRM 1
• Don't use MenACWY-D in young children with asplenia/HIV: This can impair PCV response; use MenACWY-CRM instead 1
• Don't forget booster doses: High-risk children need ongoing protection with regular boosters 1
• Don't assume MenB vaccines are available for infants: They are only licensed for ages 10-25 years 1